middle.news
How Starpharma’s Genentech Deal Sparked a $1.37 Million Profit Turnaround
8:46am on Wednesday 18th of February, 2026 AEDT
•
Biotechnology
Read Story
How Starpharma’s Genentech Deal Sparked a $1.37 Million Profit Turnaround
8:46am on Wednesday 18th of February, 2026 AEDT
Key Points
H1 FY26 revenue surged 474% to $10.8 million, boosted by $8.34 million Genentech upfront payment
Starpharma posts $1.37 million profit, reversing prior period $5.39 million loss
DEP® HER2 radiopharmaceutical program advancing towards first-in-patient trial in 2026
New research and option agreement signed with Radiopharm Theranostics
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma (ASX:SPL)
OPEN ARTICLE